Alexion Buys Out Portola, But Analysts Don’t See Value

 
• By Joseph Haas
  
SC2005_Time To Diversify_83066380_1200.jpg
Acquiring Portola and Andexxa diversifies Alexion's portfolio, but analysts don't see much growth potential
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business